SAR-BISPSMA Trademark

Trademark Overview


On Wednesday, July 10, 2024, a trademark application was filed for SAR-BISPSMA with the United States Patent and Trademark Office. The USPTO has given the SAR-BISPSMA trademark a serial number of 98641784. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, July 10, 2024. This trademark is owned by Clarity Pharmaceuticals Ltd. The SAR-BISPSMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical, medicinal, veterinary and therapeutic preparations and substances; pharmaceutical preparations and substances for diagnosis; pharmaceutical preparations and substances for therapy and treatment; pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; radiopharmaceuticals; radioprotectors; radiopharmaceuticals for use in theranostics; radiopharmaceutical products; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes; radiopharmaceuticals for medical and clinical use; radiopharmaceutical sources and norms for nuclear medicine; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceuticals for diagnosing and treating cancer; radiopharmaceuticals, particularly for the treatment of cancer; radio therapeutic preparations; chemical substance...
sar-bispsma

General Information


Serial Number98641784
Word MarkSAR-BISPSMA
Filing DateWednesday, July 10, 2024
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateWednesday, July 10, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical, medicinal, veterinary and therapeutic preparations and substances; pharmaceutical preparations and substances for diagnosis; pharmaceutical preparations and substances for therapy and treatment; pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; radiopharmaceuticals; radioprotectors; radiopharmaceuticals for use in theranostics; radiopharmaceutical products; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes; radiopharmaceuticals for medical and clinical use; radiopharmaceutical sources and norms for nuclear medicine; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceuticals for diagnosing and treating cancer; radiopharmaceuticals, particularly for the treatment of cancer; radio therapeutic preparations; chemical substances and preparations being radioactive substances for medical purposes; radioisotopes for medical purposes; diagnostic and therapeutic radioisotopes and radiochemicals for medical purposes; radiopharmaceutical preparations and substances for endo-radionuclide therapy, brachytherapy; radiopharmaceuticals used in the field of nuclear medicine, medical imaging and therapy; radiopharmaceutical preparations and substances for positron emission tomography; radiopharmaceutical preparations and substances for single photon emission tomography, target radionuclide and peptide receptor radionuclide therapy; theranostics in the field of oncology; theranostics in the field of precision oncology; radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes for treatment and diagnosis of tumours; target radiopharmaceuticals containing a target molecule; preparations for targeted radionuclide therapy; therapeutic agents for delivery of radioactive material to target sites within the body; irradiated or radioactive microspheres used for therapeutic medical purposes; radiopharmaceuticals for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; radiopharmaceuticals containing radioisotopes with short half-lives for diagnostic applications; chemicals for pharmaceutical use; chemicals for radiopharmaceuticals for diagnostic uses; pharmaceutical drugs; pharmaceutical preparations for the treatment of cancer; radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as positron emission tomography or single photon emission tomography, for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, for the treatment of tumour diseases; chemicals for radiopharmaceuticals for diagnostic uses; radiopharmaceutical drugs for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radiopharmaceutical products for diagnostic uses; radioactive pharmaceutical preparations; radioactive elements, isotopes, preparations and reagents for radioactive labelling of pharmaceutical products; radioactive pharmaceuticals and non-radioactive reagents for producing radiopharmaceuticals for diagnosis or for therapeutic use; implantable radiotherapy devices; diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use; positron emission tomography tracers for medical use; positron emission tomography tracers prepared for ingestion or injection into humans and animals; reagents for medical purposes; preparations for use in molecular imaging (for medical use); radiotherapeutic preparations; radiodiagnostic preparations; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of disease; radioactive marked substances for diagnostic purposes; radiopharmaceuticals and radioactive marked substances for therapeutic purposes; solutions for radioactive labelling; diagnostic preparations and reagents for medical use; diagnostic substances for medical use; contrasting substances for medical imaging; scanning diagnostic reagents; diagnostic imaging agents for magnetic resonance imaging; diagnostic and therapeutic chemicals for medical purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 10, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameClarity Pharmaceuticals Ltd
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressEveleigh, NSW, 2015
AU

Trademark Events


Event DateEvent Description
Wednesday, July 10, 2024NEW APPLICATION ENTERED
Wednesday, July 10, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED